Filing Flows › Health Care › Kura Oncology (KURA)
Kura Oncology (KURA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Kura Oncology (KURA) Q2 2026 earnings results →
Q2 2026 Revenue up 36% year over year to $20.9M · 327¢ of every $1 of revenue lost · operating margin -349.8%
Kura Oncology made $20.9M in Q2 2026 (+36% Y/Y): License and Collaboration Revenue $11.8M, Product $9.1M. Operating margin -349.8%, net loss $68.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $20.9M in Q2 2026, up 37% year over year and up 14% from the previous quarter. License and Collaboration Revenue was the largest line at 56% of revenue. License and Collaboration Revenue declined 23%.
Operating costs exceeded revenue by $73.0M, an operating margin of -349.8%. Total costs grew 7% against revenue growth of 37%. The fastest-growing cost line was SG&A (+26%). The quarter ended with a net loss of $68.3M, narrower than the previous quarter's $73.3M loss.
Operating cash flow was −$62.5M. Non-cash charges added back $369K of depreciation and $8.2M of share-based compensation. Capital expenditures of $656K exceeded it, leaving free cash flow of −$63.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $20.9M | +36% | -349.8% | −$68.3M | −$62.5M |
| Q1 2026 | 10-Q | May 12, 2026 | $18.3M | +30% | -431.5% | −$73.3M | −$85.9M |
| Q4 2025 | 10-K | Mar 5, 2026 | $17.3M | — | -497.6% | −$81.0M | $117M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $20.8M | — | -385.5% | −$74.1M | −$80.6M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $15.3M | — | -475.3% | −$66.1M | −$28.8M |
| Q1 2025 | 10-Q | May 1, 2025 | $14.1M | — | -458.6% | −$57.4M | −$71.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI ® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1 -mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn .
In its own words, from its 8-K, filed Aug 12, 2026.
Kura Oncology against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +36% against the peers' median +10%. Operating margin: -349.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KURA Kura Oncology | Q2 2026 | $20.9M | +36% | -349.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Kura Oncology 10-Q on SEC EDGAR · CIK 1422143 · Pharmaceutical Preparations
13F: who owns KURA and who is buying
More on KURA
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results